- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05988372
Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)
October 30, 2023 updated by: Ming Kuang, Sun Yat-sen University
Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer : a Phase II Randomized Controlled PILOT Study (SAGE)
This is a Phase II Randomized Controlled PILOT clinical study.
The purpose of this study is to explore the efficacy and safety of surufatinib and serplulimab in combination with albumin-paclitaxel and gemcitabine in the conversion therapy for patients with unresectable locally advanced pancreatic cancer.
Furthermore, it compares the efficacy of surufatinib and serplulimab in combination with albumin-paclitaxel and gemcitabine to the albumin-paclitaxel and gemcitabine regimen in the conversion therapy for patients with unresectable locally advanced pancreatic cancer.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
A total of 50 participants are expected to be enrolled in this study; 25 will receive the surufatinib and serplulimab in conjunction with albumin-paclitaxel and gemcitabine regimen and 25 will receive the AG regimen.
The participants who have been enrolled will initially undergo two cycles of albumin-paclitaxel and gemcitabine induction chemotherapy.
The researcher will assess the patients' efficacy based on their imaging results after the second cycle.
Patients with PD will be excluded from this trial, and patients with SD, PR, or CR will be enrolled.
Patients will be randomly chosen to receive either the AG regimen for 2-4 cycles or the surufatinib combined with serplulimab and AG regimen for 2-4 cycles.
Every two cycles, the researcher assessed the effectiveness of the patients' treatments and the potential for R0 resection.
Then, patients with PD were removed from the group, those who could be operated were enrolled for surgical resection, and those without PD and unable to undergo surgery were finished with a total of 6 cycles of either the AG regimen chemotherapy or surufatinib combined with serplulimab and the AG regimen chemotherapy.
Within 12 weeks of surgery, patients underwent 0-2 cycles of chemotherapy with the AG regimen or surufatinib combined with serplulimab and AG regimen, totaling 6 cycles of postoperative chemotherapy.
Then patients of AG group will enter follow up stage.
Patients with R0 resection will accept surufatinib in combination with serplulimab maintenance for no longer than 12 cycles after surgery, or until intolerability, progressive disease, death, or other criteria for study treatment discontinuation specified in the protocol, whichever comes first.
Patients who have not progressed and are unable to undergo surgery, or who accepted R1 or R2 resection, after six cycles of the surufatinib combination with serplulimab and AG regimen, will receive sulfatinib combined with serplulimab maintenance therapy for a maximum of 29 cycles, or until intolerance, disease progression, death, or other criteria specified in the study protocol were met.
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kuang Ming, Ph.D
- Phone Number: 8576 008687755766
- Email: kuangm@mail.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- First Affiliated Hospital, Sun Yat-Sen University
-
Contact:
- Kuang Ming
- Phone Number: 8576 008687755766
- Email: kuangm@mail.sysu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Written informed consent obtained from the patient prior to treatment.
- Pathologically confirmed unresectable locally advanced pancreatic cancer, received no surgical therapy.
- Age between 18 and 75 years at the time of study entry.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
- Measurable or evaluable lesions according to RECIST v1.1 criteria.
- Life expectancy ≥ 12 weeks.
- There are no serious organic diseases of the heart, lungs, brain and other organs.
Adequate functioning of the bone marrow and major organs function meeting the following criteria:
- White blood cell count ≥ 4 × 109/L, Neutrophil count ≥ 1.5 × 109/L, Platelets count ≥ 100 × 109/L,Hemoglobin ≥ 90 g/L.
- Normal coagulation function, without active bleeding or thrombotic diseases: INR ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN.
- Liver function: Total serum bilirubin ≤ 1.5 ×ULN, Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) ≤ 3 × ULN, Obstructive Jaundice with total serum bilirub ≤ 1.5 x ULN after internal/ external drainage.
- Kidney function: Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 60 mL/min.
- Cardiac function:left ventricular ejection fraction (LVEF) of 50%≥ on 2D cardiac ultrasound.
- Male or female patients of potential for childbearing who voluntarily used effective contraceptive methods such as double-barrier contraception, condoms, oral or injection avoidance or pregnancy medications, IUDs, etc during the study period and within 6 months of the last study medication . All female patients will be considered fertile unless the female patient is naturally menopausal.
Exclusion Criteria:
- Participants diagnosed pancreatic cancer with distant metastases.
- Participation in other antineoplastic drug clinical trials within 4 weeks prior to enrollment;
- Previous systemic antitumor therapy (chemotherapy, radiation, targeted or immunoth, etc.).
- Diagnosis of any second malignancy, except for adequately treated basal cell skin cancer or in situ carcinoma of the cervix uteri.
- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
- Active or prior documented autoimmune or inflammatory disorders.
- Participants are being treated with immunosuppressants, or systemic or absorbable topical hormones for immunosuppressive purposes (dose> 10 mg/day prednisone or other equivalent hormones) , and the use is still continued within 2 weeks before enrollment.
- Have undergone any surgery (other than biopsy) or invasive treatment or manipulation within 4 weeks prior to enrollment and the surgical incision has not healed completely (except intravenous catheterization, puncture drainage, internal or external drainage of obstructive jaundice, etc.)
- Participants with abnormal thyroid function who were unable to maintain thyroid function within the normal range with medical treatment.
- Hypertension that cannot be controlled in the presence of optimal treatment is defined as systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg.
- Urinary routine showed that urinary protein ≥2+, and 24-hour urinary protein>1.0g.
- Participantst currently has any disease or condition that affects the absorption of the drug, or the participants cannot take sulfatinib orally
- participants with evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding>30 mL within 3 months with hematemesis, melena, hematochezia), hemoptysis (fresh blood>5 mL within 4 weeks); Patients with history of hereditary or acquired bleeding or coagulation dysfunction, with clinically significant bleeding symptoms or definite bleeding tendency within 3 months, such as gastrointestinal bleeding and hemorrhagic gastric ulcer.
- Cardiovascular disease of significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) grade > 2 for congestive heart failure; ventricular arrhythmias requiring drug therapy; Electrocardiogram (ECG) showing QT interval ≥480 ms;
Severe infection that is active or uncontrolled:
- Inherited or acquired immunodeficiency disease,
- Known clinically significant history of liver disease, including viral hepatitis [known hepatitis B virus (HBV) carriers must exclude active HBV infection , HBV DNA positive (>1×104 copies/mL or >2000 IU/ml)];
- known hepatitis C virus infection (HCV) and positive HCV RNA (>1×103 copies/ml) or other hepatitis, cirrhosis.
- Pregnant or lactating women or participants with family planning during the trial period.
- Participants have a known history of psychotropic substance abuse, alcoholism, or drug abuse.
- The investigator believes that the participant has any clinical or laboratory abnormalities or other reasons that are unsuitable for this clinical study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Albumin-paclitaxel + Gemcitabine
enrolled, eligible patients receive Gemcitabine and Albumin-paclitaxel
|
Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
|
Experimental: Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine
enrolled, eligible patients receive Surufatinib, Serplulimab, Gemcitabine and Albumin-paclitaxel
|
Surufatinib:250mg orally once a day for 3 weeks(3 weeks 1 cycle) Serplulimab:4.5mg/Kg by intravenous infusions on day1 every 3 weeks Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
R0 Surgical Resection Rate
Time Frame: Up to 2 years
|
Proportion of patients with negative microscopic margins (no tumor cell remains)
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Surgical conversion rate
Time Frame: Up to 2 years
|
Surgical conversion rate: the proportion of patients with successful conversion and surgical resection in all patients, surgical conversion rate =(number of patients with successful conversion and surgical resection/total number of patients) ×100%.
|
Up to 2 years
|
Objective response rate (ORR)
Time Frame: Up to 2 years
|
ORR is defined as the percentage of patients who have achieved complete response (CR) or partial response (PR), as measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
|
Up to 2 years
|
Deepness of response (DpR)
Time Frame: Up to 2 years
|
DpR is defined as the percentage of maximal tumor reduction from baseline of a target lesion.
|
Up to 2 years
|
Progression-Free Survival (PFS)
Time Frame: Up to 2 years
|
PFS is defined as the time from the first dose of administration to progression or death
|
Up to 2 years
|
Disease-free survival (DFS)
Time Frame: Up to 2 years
|
DFS is defined as the time interval between the date of enrollment and the date of the first documented evidence of relapse after radical resection at any site or death related to cancer
|
Up to 2 years
|
Over Survival (OS)
Time Frame: Up to 2 years
|
OS is defined as the time from first treatment to death, regardless of disease recurrence
|
Up to 2 years
|
Quality of Life (QOL)
Time Frame: Up to 2 years
|
Acording the EORTC QLQ-C30.
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 23, 2023
Primary Completion (Estimated)
October 23, 2023
Study Completion (Estimated)
October 23, 2026
Study Registration Dates
First Submitted
August 4, 2023
First Submitted That Met QC Criteria
August 4, 2023
First Posted (Actual)
August 14, 2023
Study Record Updates
Last Update Posted (Actual)
November 1, 2023
Last Update Submitted That Met QC Criteria
October 30, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Albumin-Bound Paclitaxel
- Gemcitabine
Other Study ID Numbers
- LAPC2023
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Pancreatic Cancer
-
Washington University School of MedicineNational Cancer Institute (NCI)RecruitingCervical Cancer | Pancreatic Cancer | Pancreas Cancer | Locally Advanced Cervical Carcinoma | Locally Advanced Cervical Cancer | Cancer of the Pancreas | Locally Advanced Pancreatic Carcinoma | Locally Advanced Pancreatic Cancer | Cancer of the Cervix | Locally Advanced Pancreas CancerUnited States
-
Michael ChuongNovoCure Ltd.RecruitingPancreas Cancer | Locally Advanced Pancreatic Adenocarcinoma | Locally AdvancedUnited States
-
UMC UtrechtRadboud University Medical Center; Catharina Ziekenhuis Eindhoven; Amsterdam... and other collaboratorsNot yet recruitingLocally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy (LAPSTAR)Locally Advanced Pancreatic AdenocarcinomaNetherlands
-
Institut du Cancer de Montpellier - Val d'AurelleRecruitingLocally Advanced Pancreatic AdenocarcinomaFrance
-
National Cancer Institute (NCI)SuspendedStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Locally Advanced Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Unresectable Pancreatic AdenocarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI)Active, not recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal...United States
-
Istituto Scientifico Romagnolo per lo Studio e...CompletedUnresectable Pancreatic Cancer | Locally Advanced Pancreatic Cancer | Nonmetastatic Pancreatic CancerItaly
-
Boryung Pharmaceutical Co., LtdRecruitingMetastatic Pancreatic Cancer | Locally Advanced Pancreatic CancerKorea, Republic of
-
AIO-Studien-gGmbHServier Deutschland GmbH; Crolll GmbhActive, not recruitingMetastatic Pancreatic Cancer | Locally Advanced Pancreatic CancerGermany
-
Yonsei UniversityActive, not recruitingMetastatic Pancreatic Cancer | Locally Advanced Pancreatic CancerKorea, Republic of
Clinical Trials on Albumin-paclitaxel + Gemcitabine
-
Anne NoonanNational Cancer Institute (NCI)RecruitingStage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic AdenocarcinomaUnited States
-
Muhammad FurqanCelgene CorporationActive, not recruitingSmall Cell Lung Cancer (SCLC)United States
-
Jiangsu Healthy Life Innovation Medical Technology...Not yet recruitingLocally Advanced Pancreatic CancerChina
-
Chinese Society of Lung CancerCompletedCarcinoma, Non-Small-Cell LungChina
-
AIO-Studien-gGmbHCelgene; ClinAssess GmbHCompletedResectable Pancreatic Cancer | Ductal Adenocarcinoma of the PancreasGermany
-
Shanghai Zhongshan HospitalFudan UniversityRecruitingUnresectable Locally Advanced or Metastatic Pancreatic CancerChina
-
HutchmedNot yet recruiting
-
Jinling Hospital, ChinaJiangsu Hengrui Pharmaceutical Co., Ltd.RecruitingPancreatic Cancer | Neoadjuvant TherapyChina
-
Trishula Therapeutics, Inc.AbbVieRecruitingPancreatic CancerUnited States
-
AstraZenecaRecruitingBiliary Tract CancerFrance, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore